KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2-breast cancer

被引：0
|
作者：
Cardoso, F. [1 ]
Bardia, A. [2 ]
Andre, F. [3 ]
Cescon, D. W. [4 ]
McArthur, H. [5 ]
Telli, M. [6 ]
Loi, S. [7 ]
Cortes, J. [8 ]
Schmid, P. [9 ]
Harbeck, N. [10 ]
Denkert, C. [11 ]
Jackisch, C. [12 ]
Jia, L. [13 ]
Hirshfield, K. [14 ]
Karantza, V. [15 ]
机构：
[1] Champalimaud Fdn Canc Ctr, Breast Unit, Lisbon, Portugal
[2] Harvard Med Sch, Massachusetts Gen Hosp, Med Oncol, Boston, MA 02115 USA
[3] Gustave Roussy Canc Campus, Med Oncol Dept, Breast Canc Unit, Villejuif, France
[4] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[5] Cedars Sinai Med Ctr, Breast Oncol, Los Angeles, CA 90048 USA
[6] Stanford Univ, Sch Med, Med Med Oncol, Stanford, CA USA
[7] Peter MacCallum Canc Ctr, Div Res, Translat Breast Canc Genom Lab, Melbourne, Vic, Australia
[8] Ramon & Cajal Univ Hosp, Breast Canc Program, Madrid, Spain
[9] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[10] Ludwig Maximilians Univ Grosshadern, Breast Ctr, Munich, Germany
[11] Uniklinikum Giessen & Marburg, Inst Pathol, Marburg, Germany
[12] Klinikum Offenbach GmbH, Obstet & Gynecol, Offenbach, Germany
[13] Merck & Co Inc, Biostat, Kenilworth, NJ USA
[14] Merck & Co Inc, Oncol Late Stage Dev, Kenilworth, NJ USA
[15] Merck & Co Inc, Clin Res Oncol, Kenilworth, NJ USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
24TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [21] KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
    Wakelee, Heather A.
    Liberman, Moishe
    Kato, Terufumi
    Tsuboi, Masahiro
    Lee, Se-Hoon
    He, Jie
    Gao, Shugeng
    Chen, Ke-Neng
    Dooms, Christophe Alfons
    Majem, Margarita
    Eigendorff, Ekkehard
    Martinengo, Gaston Lucas
    Bylicki, Olivier
    Rodriguez-Abreu, Delvys
    Chaft, Jamie E.
    Novello, Silvia
    Yang, Jing
    Keller, Steven M.
    Samkari, Ayman
    Spicer, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA100 - LBA100
  • [22] Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.
    Luke, Jason J.
    Ascierto, Paolo Antonio
    Carlino, Matteo S.
    Eggermont, Alexander M. M.
    Grob, Jean-Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina V.
    Mohr, Peter
    Robert, Caroline
    Gershenwald, Jeffrey E.
    Poklepovic, Andrew Stewart
    Ross, Merrick I.
    Scolyer, Richard A.
    Yoon, Charles
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Sondak, Vernon K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [23] Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
    Bruges Maya, R.
    Urrego, J. C.
    Marrugo, C.
    Wurcel, V.
    Khandelwal, A.
    Singh, J.
    Huang, M.
    Haiderali, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S286 - S286
  • [24] KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
    Wakelee, Heather A.
    Liberman, Moishe
    Kato, Terufumi
    Tsuboi, Masahiro
    Lee, Se-Hoon
    He, Jie
    Gao, Shugeng
    Chen, Ke-Neng
    Dooms, Christophe Alfons
    Majem, Margarita
    Eigendorff, Ekkehard
    Martinengo, Gaston Lucas
    Bylicki, Olivier
    Rodriguez-Abreu, Delvys
    Chaft, Jamie E.
    Novello, Silvia
    Yang, Jing
    Keller, Steven M.
    Samkari, Ayman
    Spicer, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [25] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, V.
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K. S.
    Salman, P.
    Hoyos, E.
    Yanez, E.
    Gumus, M.
    De Mendoza, M. Olivera Hurtado
    Samouelian, V.
    Castonguay, V.
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S. M.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1307 - S1308
  • [26] A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).
    Goss, P. E.
    Barrios, C. H.
    Bell, R.
    Finkelstein, D.
    Iwata, H.
    Martin, M.
    Braun, A. H.
    Dansey, R. D.
    Coleman, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
    Dent, Rebecca
    Cortes, Javier
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Bergh, Jonas
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Haiderali, Amin
    Jia, Liyi
    Nguyen, Allison Martin
    Pan, Wilbur
    O'Shaughnessy, Joyce
    Schmid, Peter
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (10): : 1654 - 1663
  • [28] Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER, part 1)
    Spring, Laura M.
    Scarpetti, Lauren
    Niemierko, Andrzej
    Isakoff, Steven J.
    Moy, Beverly
    Wander, Seth A.
    Smith, Elisabeth
    Abraham, Elizabeth
    Shin, Jennifer
    Patel, Jaymin M.
    Comander, Amy
    Mulvey, Therese
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [29] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis
    Cortes, J.
    Haiderali, A.
    Huang, M.
    Pan, W.
    Fox, G. E.
    Park, J.
    Frederickson, A. M.
    Fasching, P. A.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S615 - S616
  • [30] Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
    Andrea Favre-Bulle
    Min Huang
    Amin Haiderali
    Arjun Bhadhuri
    PharmacoEconomics - Open, 2024, 8 : 91 - 101
12345